Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.

Biotechnology

Education

Parthenon Therapeutics

Laurent Audoly

Rena Yan

Christopher O’donnell

Irena Lerentracht Webster

Xinwei Sher

Paula Bucko

Joshua Merritt

Yan Qin

Ryan Newton

Fredrick Gootkind

Heather Condurso

Amy Mueller

Ziyin Wang

Thomas Schürpf

Peter Cincotta

Marianna Murphy

Lisa Gaynes

Susan G. MacDonald

Joseph Paul Eder

The Scientific Team at Parthenon Therapeutics focuses on researching and developing innovative anti-cancer therapies that target and reprogram the tumor microenvironment (TME). They conduct rigorous studies to understand the interplay between cancer cells and the TME, design and test novel drug candidates like PRTH-101, and aim to identify the most effective treatments for different patient populations. Their work is pivotal in overcoming the barriers that shield tumors from the immune system, ultimately advancing the efficacy of cancer therapies.

Scientific Team

Leadership Team

Clinical and Medical Team

Scientific Team

About

Team members

Other teams at Parthenon Therapeutics

Leadership Team

Clinical and Medical Team